Cocaine Esterase Mutant for BZE Hydrolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cocaine abuse are inadequate as they fail to efficiently eliminate the toxicity of cocaine and its metabolite benzoyllecgonine (BZE), which contributes to long-term toxicity and environmental pollution, due to low catalytic efficiency of existing cocaine esterase enzymes.
Innovation Solution
A high-activity cocaine esterase mutant is designed through site-directed mutagenesis and expressed using a prokaryotic cell system, enhancing the enzyme's ability to hydrolyze BZE into non-toxic ecgonine and benzoic acid, with specific mutations such as V116K, T172R/G173Q/L196C/I301C/A51L, and others, significantly improving catalytic efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural BChE is used to hydrolyze BZE, then the toxicity of BZE is eliminated, but the recombinant expression is difficult due to high glycosylation
Solution Approach 1:
The patent uses a prokaryotic expression system (E. coli) to produce the CocE enzyme, which can be easily expressed and purified without the complex glycosylation issues associated with eukaryotic systems. This allows for cost-effective, large-scale production of the enzyme for clinical applications
Solution Approach 2:
The patent employs site-directed mutagenesis to create specific amino acid mutations (V116K, T172R/G173Q/L196C/I301C/A51L, etc.) in the CocE enzyme sequence. These parameter changes in the protein structure optimize its catalytic activity toward BZE hydrolysis while maintaining ease of prokaryotic expression
2Ease of manufacture
If natural CocE is used to express BZE, then the expression is economical and safe, but the catalytic efficiency to BZE is too low
Solution Approach 1:
The patent applies multiple site-directed mutations to the CocE enzyme sequence, including V116K, T172R/G173Q/L196C/I301C/A51L, and other combinations. These parameter changes in the amino acid sequence significantly enhance the catalytic efficiency of BZE hydrolysis while preserving the enzyme's safety profile and expressibility in prokaryotic systems
Solution Approach 2:
The patent creates composite enzyme variants by combining multiple mutations in the CocE protein structure. The composite mutant enzymes exhibit synergistic effects where multiple amino acid changes work together to optimize both catalytic efficiency and substrate specificity for BZE
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The high-activity cocaine esterase mutant effectively accelerates the metabolism of BZE, rapidly converting it into non-toxic metabolites, demonstrating improved safety and efficacy in both in vitro and in vivo settings, thus addressing the limitations of existing treatments.
Implementation Method 1
hydrolyze BZE into non-toxic ecgonine and benzoic acid
Implementation Method 2
cocaine esterase mutant effectively accelerates the metabolism of BZE
Data Source
AI summary
Disclosed are a cocaine esterase mutant and use thereof. The cocaine esterase mutant is obtained by mutating a wildtype cocaine esterase, an amino acid sequence of the wildtype cocaine esterase is shown as SEQ ID No. 1, the cocaine esterase mutant is T172R/G173Q/L196C/I301C, or additionally added with V116K point mutation, or additionally added with A51 site mutation, and the A51 site mutation is L, Y, V, F or W. Catalytic efficiency of the cocaine esterase mutant screened on a cocaine toxic metabolite benzoylecgonine is greatly improved compared with that of a wildtype enzyme.